RECOMBINANT HUMAN GROWTH HORMONE (NUTROPIN) IN CHILDREN POST RENAL TRANSPLANT

儿童肾移植后的重组人类生长激素（NUTROPIN）

• 批准号: 6244713
• 负责人: JOSEPH T FLYNN
• 金额: $ 2.22万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-20 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6244713
• 关键词: child (0-11); child physical development; chronic renal failure; clinical research; clinical trials; drug screening /evaluation; hormone therapy; human subject; human therapy evaluation; kidney transplantation; pediatric pharmacology; pediatrics; postoperative state; preoperative state; recombinant proteins; somatotropin

Poor growth in children with renal failure (CRF) may not be corrected with renal transplantation. Recombinant human growth hormone (rhGH), now in use to treat children with CRF pre-transplantation, may be effective post-transplantation as well, but may cause unique problems such as chronic rejection. This study is intended to study the efficacy and safety of rhGH treatment in this population.

肾功能衰竭（CRF）儿童的生长不良可能无法纠正 肾移植 重组人生长激素（rhGH）， 目前用于治疗移植前CRF儿童， 有效的移植后，以及，但可能会导致独特的问题 例如慢性排斥。 本研究旨在研究 rhGH治疗的安全性。